Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oncolin Therapeutics, formerly known as Edgeline Holdings, has announced that one of its research programs was awarded a National Institute of Health Grant for $179,000 to support research on thermally targeted delivery of Doxorubicin.
Subscribe to our email newsletter
Preliminary results reported in this grant demonstrated that specific polypeptide doxorubicin conjugates showed increased cytoxicity and decreased toxicity when used in conjunction with hyperthermia. Specific targeting of the proposed chemotherapeutic polypeptide carriers to solid tumors by local hyperthermia is said to increase specificity and efficacy of treatment and reduce the toxicity to normal tissues. According to the company the research will be expanded to other drugs and animal testing to choose the best candidate to bring into clinical development.
Donald Picker, COO of Oncolin, said: “We are very happy that this program has received funding from such a prestigious organization as the NIH to help progress this potential platform technology.”